Loading...
Psoriatic arthritis continues to be associated with morbidity and deformity despite multiple agents for its management (e.g., tumor necrosis factor inhibitors, other biologic agents, the recently approved oral agent apremilast). Therefore, development of new agents with alternate mechanisms of action remains necessary. To that end, investigators tested the benefits for psoriatic arthritis of brodalumab, a human monoclonal antibody against the interleukin-17 receptor A that is currently under development for psoriasis. In a multi-institutional, randomized, placebo-controlled phase 2 study, 168 patients received placebo or brodalumab 140 mg or 280 mg weekly for the first 2 weeks, then biweekly (total, 7 doses). At week 12, remaining participa…